DiaMedica Therapeutics Inc. (DMAC) Financials

DMAC

FY2025 annual

Revenue Not reported for FY2025

Net Income -$32.8M -34.0% YoY

Free Cash Flow -$29.1M -31.7% YoY

Operating Cash Flow -$29.1M -31.6% YoY

Market Cap $430.9M as of Oct 8, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 11.2x on $38.3M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 8, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 10, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the DMAC SEC filings page.

This page shows DiaMedica Therapeutics Inc. (DMAC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI DMAC FY2025 2026-10-04

The business is funding a widening development effort externally, with losses converting almost directly into cash outflows.

Between FY2023 and FY2025, net loss widened from $19.4M to $32.8M. The close match between FY2025 net loss and operating cash flow, with free cash flow almost the same, indicates that reported losses are translating into cash use rather than reflecting large noncash charges or working-capital swings.

Research and development nearly doubled from $13.1M in FY2023 to $24.6M in FY2025. That expansion coincided with operating cash outflow reaching $29.1M in FY2025 versus $18.7M in FY2023, pointing to an accelerating development-stage spending pattern rather than a scaled commercial engine.

FY2025 financing cash inflow of $43.9M exceeded operating cash outflow of $29.1M, showing that balance-sheet growth depended on outside financing during the year. Total assets rose from $46.3M to $61.4M while liabilities remained comparatively modest, and the reported liquidity measure equaled 24.7 months of the latest annual operating outflow.

Financial Health Signals

Financial health score not available

DiaMedica Therapeutics Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/6

DiaMedica Therapeutics Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

DiaMedica Therapeutics Inc. reported a net loss of $32.8M while operations used $29.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$10.5M

YoY-31.0%

QoQ-0.1%

DiaMedica Therapeutics Inc.'s EBITDA was -$10.5M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 31.0% from the same quarter a year earlier. Against the prior quarter it is down 0.1%.

Net Income

-$10.1M

YoY-31.7%

QoQ-1.0%

DiaMedica Therapeutics Inc. reported -$10.1M in net income in Q2 2026. This represents a decrease of 31.7% from the same quarter a year earlier. Against the prior quarter it is down 1.0%.

Revenue

Not reported for Q2 2026.

EPS (Diluted)

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$8.1M

YoY-6.7%

QoQ+10.7%

DiaMedica Therapeutics Inc. recorded an outflow of $8.1M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 6.7% from the same quarter a year earlier. Against the prior quarter it is up 10.7%.

Cash & Debt

$5.1M

YoY+24.8%

QoQ+5.4%

5Y CAGR+18.1%

DiaMedica Therapeutics Inc. held $5.1M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

54M

YoY+4.3%

QoQ+0.1%

5Y CAGR+23.5%

DiaMedica Therapeutics Inc. had 54M shares outstanding in Q2 2026. This represents an increase of 4.3% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-26.5%

YoY+1.9pp

QoQ-5.2pp

DiaMedica Therapeutics Inc.'s ROE was -26.5% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 1.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.2 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$8.2M

YoY+40.0%

QoQ+2.1%

DiaMedica Therapeutics Inc. invested $8.2M in research and development in Q2 2026. This represents an increase of 40.0% from the same quarter a year earlier. Against the prior quarter it is up 2.1%.

Capital Expenditures

$3K

YoY-50.0%

QoQ-62.5%

5Y CAGR-5.6%

DiaMedica Therapeutics Inc. invested $3K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 50.0% from the same quarter a year earlier. Against the prior quarter it is down 62.5%.

Share Buybacks

Not reported for Q2 2026.

DMAC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DMAC quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$500K	N/A
R&D Expenses	N/A	$24.6M+29.2%	$19.1M+45.4%	$13.1M+67.2%	$7.8M-10.6%	$8.8M+6.8%	$8.2M+3.9%	$7.9M+74.7%	$4.5M+41.0%	$3.2M
SG&A Expenses	N/A	$9.8M+28.3%	$7.6M-6.5%	$8.2M+32.4%	$6.2M+26.2%	$4.9M+8.6%	$4.5M+21.7%	$3.7M+34.8%	$2.7M+108.6%	$1.3M
Operating Income	N/A	-$34.4M-28.9%	-$26.7M-25.5%	-$21.3M-51.9%	-$14.0M-2.6%	-$13.6M-7.5%	-$12.7M-9.5%	-$11.6M-71.5%	-$6.8M-49.6%	-$4.5M
EBITDA	N/A	-$34.4M-28.9%	-$26.6M-25.5%	-$21.2M-52.0%	-$14.0M-2.6%	-$13.6M-7.4%	-$12.7M-9.6%	-$11.6M-71.5%	-$6.7M-49.4%	-$4.5M
Income Tax	N/A	$28K-6.7%	$30K-30.2%	$43K+53.6%	$28K0.0%	$28K+3.7%	$27K-12.9%	$31K-61.3%	$80K	N/A
Net Income	N/A	-$32.8M-34.0%	-$24.4M-26.1%	-$19.4M-41.7%	-$13.7M-0.6%	-$13.6M-10.6%	-$12.3M-15.4%	-$10.6M-85.7%	-$5.7M-34.6%	-$4.3M
EPS (Basic)	N/A	-$0.70-16.7%	-$0.600.0%	-$0.60-15.4%	-$0.52+20.0%	-$0.65	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$8.2M+40.0%	$8.0M+41.2%	N/A	$6.4M+29.2%	$5.8M+48.2%	$5.7M+53.9%	N/A	$5.0M+52.3%
SG&A Expenses	$2.3M+7.3%	$2.5M+0.3%	N/A	$2.6M+36.6%	$2.2M+27.8%	$2.5M+20.5%	N/A	$1.9M+0.8%
Operating Income	-$10.5M-31.1%	-$10.5M-28.7%	N/A	-$9.0M-31.2%	-$8.0M-42.0%	-$8.1M-41.9%	N/A	-$6.9M-33.5%
EBITDA	-$10.5M-31.0%	-$10.5M-28.7%	N/A	-$9.0M-31.2%	-$8.0M-42.2%	-$8.1M-41.9%	N/A	-$6.9M-33.5%
Income Tax	$7K+16.7%	$7K+16.7%	N/A	$6K-14.3%	$6K-14.3%	$6K-14.3%	N/A	$7K0.0%
Net Income	-$10.1M-31.7%	-$10.0M-30.3%	N/A	-$8.6M-37.4%	-$7.7M-50.4%	-$7.7M-49.6%	N/A	-$6.3M-40.3%
EPS (Basic)	-$0.19-5.6%	-$0.19-5.6%	-$0.17+5.6%	-$0.17-13.3%	-$0.18-38.5%	-$0.18-28.6%	-$0.18-28.6%	-$0.15-25.0%

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense, EPS (Diluted), Diluted Shares (Avg).

DMAC Balance Sheet

DMAC quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Total Assets	$61.4M+32.4%	$46.3M-14.4%	$54.2M+57.5%	$34.4M-24.5%	$45.6M+62.1%	$28.1M+210.3%	$9.1M-50.6%	$18.3M+917.7%	$1.8M
Current Assets	$60.6M+35.9%	$44.6M-16.9%	$53.7M+58.6%	$33.8M-25.5%	$45.4M+62.7%	$27.9M+216.0%	$8.8M-50.8%	$18.0M+1102.9%	$1.5M
Cash & Equivalents	$15.6M+417.3%	$3.0M-33.4%	$4.5M-3.9%	$4.7M+0.4%	$4.7M-36.5%	$7.4M+90.8%	$3.9M-76.9%	$16.8M+1143.4%	$1.4M
Short-Term Investments	$44.2M+7.6%	$41.1M-15.0%	$48.4M+68.0%	$28.8M-28.8%	$40.4M+101.0%	$20.1M+403.1%	$4.0M	$0	$0
Accounts Receivable	$258K+9.3%	$236K-36.0%	$369K+350.0%	$82K-36.9%	$130K-61.8%	$340K-58.7%	$823K+5.5%	$780K+875.0%	$80K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$5.3M-6.5%	$5.6M+81.3%	$3.1M+20.8%	$2.6M+68.2%	$1.5M-26.6%	$2.1M+44.9%	$1.4M+9.3%	$1.3M+31.0%	$1.0M
Current Liabilities	$5.1M-4.8%	$5.4M+93.5%	$2.8M+28.5%	$2.2M+42.3%	$1.5M-24.9%	$2.0M+53.9%	$1.3M+1.7%	$1.3M+29.2%	$1.0M
Non-Current Liabilities	$128K-46.0%	$237K-25.2%	$317K-20.8%	$400K+13233.3%	$3K-94.3%	$53K-55.1%	$118K+555.6%	$18K	$0
Total Equity	$56.1M+37.8%	$40.7M-20.2%	$51.1M+60.4%	$31.8M-27.7%	$44.0M+69.2%	$26.0M+241.5%	$7.6M-55.3%	$17.0M+2030.8%	$799K
Retained Earnings	-$172.8M-23.4%	-$140.0M-21.2%	-$115.6M-20.2%	-$96.2M-16.6%	-$82.5M-19.7%	-$68.9M-21.7%	-$56.6M-23.2%	-$46.0M-14.3%	-$40.2M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$45.0M+43.0%	$53.1M+36.7%	$61.4M+32.4%	$57.0M+8.6%	$31.5M-44.6%	$38.8M-21.2%	$46.3M-14.4%	$52.5M-9.7%
Current Assets	$44.3M+42.6%	$52.4M+39.9%	$60.6M+35.9%	$56.2M+10.7%	$31.1M-43.5%	$37.4M-21.2%	$44.6M-16.9%	$50.8M+6.0%
Cash & Equivalents	$5.1M+24.8%	$4.9M+88.0%	$15.6M+417.3%	$3.3M-19.5%	$4.1M-70.8%	$2.6M+23.5%	$3.0M-33.4%	$4.1M+85.2%
Short-Term Investments	$38.4M+48.0%	$46.5M+37.7%	$44.2M+7.6%	$52.0M+12.9%	$25.9M-35.2%	$33.7M-24.1%	$41.1M-15.0%	$46.1M+4.1%
Accounts Receivable	$244K+51.6%	$301K+19.0%	$258K+9.3%	$260K-10.3%	$161K-58.8%	$253K-36.6%	$236K-36.0%	$290K-6.5%
Long-Term Investments	$0	$0-100.0%	$0	$0	$0	$1.0M	$0	$0-100.0%
Total Liabilities	$6.7M+55.0%	$5.8M+19.9%	$5.3M-6.5%	$5.4M+19.0%	$4.3M+27.4%	$4.9M+67.5%	$5.6M+81.3%	$4.6M+81.7%
Current Liabilities	$6.6M+60.2%	$5.7M+23.2%	$5.1M-4.8%	$5.3M+22.6%	$4.1M+33.3%	$4.7M+78.3%	$5.4M+93.5%	$4.3M+98.0%
Non-Current Liabilities	$69K-62.5%	$97K-54.0%	$128K-46.0%	$157K-40.3%	$184K-36.1%	$211K-28.2%	$237K-25.2%	$263K-22.6%
Total Equity	$38.3M+41.1%	$47.2M+39.1%	$56.1M+37.8%	$51.6M+7.6%	$27.2M-49.1%	$34.0M-26.7%	$40.7M-20.2%	$48.0M-13.8%
Retained Earnings	-$192.9M-24.2%	-$182.8M-23.8%	-$172.8M-23.4%	-$164.0M-24.2%	-$155.4M-23.5%	-$147.7M-22.4%	-$140.0M-21.2%	-$132.1M-19.7%

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

DMAC Cash Flow Statement

DMAC quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Operating Cash Flow	-$31.5M	-$29.1M-31.6%	-$22.1M-17.9%	-$18.7M-62.7%	-$11.5M+6.0%	-$12.3M-33.4%	-$9.2M-0.9%	-$9.1M-59.8%	-$5.7M-46.1%	-$3.9M
Depreciation & Amortization	N/A	$43K+10.3%	$39K+30.0%	$30K+20.0%	$25K+4.2%	$24K+14.3%	$21K0.0%	$21K+40.0%	$15K+275.0%	$4K
Stock-Based Compensation	N/A	$3.8M+84.5%	$2.1M+23.9%	$1.7M+12.1%	$1.5M-3.6%	$1.6M-15.5%	$1.8M+58.3%	$1.2M+87.7%	$620K+51.6%	$409K
Capital Expenditures	$33K	$40K+60.0%	$25K+4.2%	$24K-70.4%	$81K+268.2%	$22K-53.2%	$47K+2250.0%	$2K-96.0%	$50K+127.3%	$22K
Free Cash Flow	-$31.5M	-$29.1M-31.7%	-$22.1M-17.9%	-$18.8M-61.8%	-$11.6M+5.6%	-$12.3M-33.0%	-$9.2M-1.4%	-$9.1M-58.4%	-$5.7M-46.5%	-$3.9M
Investing Cash Flow	-$11.6M	-$2.2M-125.6%	$8.6M+146.8%	-$18.3M-258.6%	$11.5M+156.2%	-$20.5M-27.3%	-$16.1M-312.8%	-$3.9M-7716.0%	-$50K-127.3%	-$22K
Financing Cash Flow	$44.2M	$43.9M+265.8%	$12.0M-67.4%	$36.8M+614133.3%	-$6K-100.0%	$30.1M+4.3%	$28.8M+41107.1%	$70K-99.7%	$21.2M+499.5%	$3.5M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$8.1M-6.8%	-$9.1M-27.0%	-$7.8M-20.7%	-$6.5M-46.5%	-$7.6M-68.1%	-$7.1M-7.5%	-$6.4M-68.8%	-$4.5M+6.8%
Depreciation & Amortization	$12K+300.0%	$11K0.0%	$11K0.0%	$18K+80.0%	$3K-70.0%	$11K+37.5%	$11K+37.5%	$10K+25.0%
Stock-Based Compensation	$1.1M+45.0%	$822K-5.2%	N/A	$1.0M+79.8%	$771K+74.0%	$867K+77.7%	N/A	$565K+32.9%
Capital Expenditures	$3K-50.0%	$8K-33.3%	$6K-14.3%	$16K+77.8%	$6K	$12K+33.3%	$7K+133.3%	$9K-10.0%
Free Cash Flow	-$8.1M-6.7%	-$9.1M-26.9%	-$7.8M-20.6%	-$6.6M-46.6%	-$7.6M-68.3%	-$7.2M-7.5%	-$6.4M-68.8%	-$4.5M+6.8%
Investing Cash Flow	$8.2M-8.0%	-$2.1M-131.9%	$8.0M+53.6%	-$25.8M-361.3%	$9.0M+89.1%	$6.6M+57.4%	$5.2M-15.0%	-$5.6M-567.0%
Financing Cash Flow	$132K-18.0%	$417K+358.2%	$12.1M+9975.8%	$31.5M+25536.6%	$161K-98.6%	$91K+9200.0%	$120K+12100.0%	$123K+2150.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

DMAC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DMAC quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-1352.2%	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-1146.8%	N/A
Return on Equity	-58.4%+1.6pp	-60.0%-22.1pp	-38.0%+5.0pp	-43.0%-12.1pp	-30.9%+16.4pp	-47.3%+92.6pp	-139.8%-106.1pp	-33.7%+499.5pp	-533.2%
Return on Assets	-53.4%-0.7pp	-52.7%-17.0pp	-35.8%+4.0pp	-39.8%-9.9pp	-29.8%+13.9pp	-43.8%+73.9pp	-117.6%-86.4pp	-31.3%+205.1pp	-236.4%
Current Ratio	11.81+3.5x	8.28-11.0x	19.27+3.7x	15.61-14.2x	29.82+16.0x	13.77+7.1x	6.70-7.2x	13.87+12.4x	1.49
Debt-to-Equity	0.090.0x	0.14+0.1x	0.060.0x	0.080.0x	0.030.0x	0.08-0.1x	0.19+0.1x	0.08-1.2x	1.26
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.03	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-1149.2%	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-26.5%+1.9pp	-21.3%+1.4pp	N/A	-16.7%-3.6pp	-28.3%-18.8pp	-22.7%-11.6pp	N/A	-13.1%-5.0pp
Return on Assets	-22.5%+1.9pp	-18.9%+0.9pp	N/A	-15.1%-3.2pp	-24.5%-15.5pp	-19.9%-9.4pp	N/A	-11.9%-4.3pp
Current Ratio	6.72-0.8x	9.11+1.1x	11.81+3.5x	10.67-1.1x	7.55-10.3x	8.02-10.1x	8.28-11.0x	11.81-10.3x
Debt-to-Equity	0.170.0x	0.120.0x	0.090.0x	0.110.0x	0.16+0.1x	0.14+0.1x	0.14+0.1x	0.10+0.1x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
DiaMedica Therapeutics Inc. DMAC	FY2025	N/A	-$32.8M	N/A	$430.9M	—
Larimar Therapeutics, Inc. LRMR	FY2025	N/A	-$165.7M	N/A	$285.7M	—
Astria Therapeutics, Inc. ATXS	FY2024	N/A	-$94.3M	N/A	$718.1M	—
Solid Biosciences Inc. SLDB	FY2025	N/A	-$174.3M	N/A	$734.5M	—
Inhibrx Biosciences, Inc. INBX	FY2025	$1.3M	-$140.1M	N/A	$1.4B	21/100
Lexicon Pharmaceuticals, Inc. LXRX	FY2025	$49.8M	-$50.3M	N/A	$783.1M	65/100

Where DiaMedica Therapeutics Inc. Ranks

Frequently Asked Questions

Is DiaMedica Therapeutics Inc. profitable?

No, DiaMedica Therapeutics Inc. (DMAC) reported a net income of -$32.8M in fiscal year 2025.

What is DiaMedica Therapeutics Inc.'s EBITDA?

DiaMedica Therapeutics Inc. (DMAC) had EBITDA of -$34.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is DiaMedica Therapeutics Inc.'s return on equity (ROE)?

DiaMedica Therapeutics Inc. (DMAC) has a return on equity of -58.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is DiaMedica Therapeutics Inc.'s free cash flow?

DiaMedica Therapeutics Inc. (DMAC) recorded an outflow of $29.1M in free cash flow during fiscal year 2025. This represents a -31.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is DiaMedica Therapeutics Inc.'s operating cash flow?

DiaMedica Therapeutics Inc. (DMAC) recorded an outflow of $29.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are DiaMedica Therapeutics Inc.'s total assets?

DiaMedica Therapeutics Inc. (DMAC) had $61.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are DiaMedica Therapeutics Inc.'s capital expenditures?

DiaMedica Therapeutics Inc. (DMAC) invested $40K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does DiaMedica Therapeutics Inc. spend on research and development?

DiaMedica Therapeutics Inc. (DMAC) invested $24.6M in research and development during fiscal year 2025.

How many shares does DiaMedica Therapeutics Inc. have outstanding?

DiaMedica Therapeutics Inc. (DMAC) had 54M shares outstanding as of fiscal year 2025.

What is DiaMedica Therapeutics Inc.'s current ratio?

DiaMedica Therapeutics Inc. (DMAC) had a current ratio of 11.81 as of fiscal year 2025, which is generally considered healthy.

What is DiaMedica Therapeutics Inc.'s debt-to-equity ratio?

DiaMedica Therapeutics Inc. (DMAC) had a debt-to-equity ratio of 0.09 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is DiaMedica Therapeutics Inc.'s return on assets (ROA)?

DiaMedica Therapeutics Inc. (DMAC) had a return on assets of -53.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is DiaMedica Therapeutics Inc.'s P/E ratio?

DiaMedica Therapeutics Inc. (DMAC) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $430.9M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is DiaMedica Therapeutics Inc.'s price-to-sales ratio?

DiaMedica Therapeutics Inc. (DMAC) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $430.9M as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does DiaMedica Therapeutics Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, DiaMedica Therapeutics Inc. (DMAC) held $59.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $29.1M over that year. Dividing the one by the other, the reported balance equals about 25 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is DiaMedica Therapeutics Inc.'s Piotroski F-Score?

DiaMedica Therapeutics Inc. (DMAC) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are DiaMedica Therapeutics Inc.'s earnings high quality?

DiaMedica Therapeutics Inc. (DMAC) reported a net loss of $32.8M while operations used $29.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.